Cambridge Innovation Capital
Edit

Cambridge Innovation Capital

https://www.cic.vc
Last activity: 24.06.2026
Active
Invests in categories: AIBioTechDataHealthTechInformationLegalTechNewsPlatformSoftwareTechnology
Cambridge Innovation Capital is a leading venture investor in Cambridge backing and building category-leading deep tech and life sciences companies. CIC currently manages over £275 million and has invested in 30+ companies.
CIC is also a preferred investor for the University of Cambridge, Europe’s top source of founders for venture-backed start-ups.
For more information visit www.cic.vc or follow @CambsInnovation
News
678
Portfolio
44
Mentions
86
Location: United Kingdom, England, Cambridge
Employees: 51-200
Founded date: 2013
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A; Series B

Portfolio 44

DateNameWebsiteTotal RaisedLocation
21.04.2026Companiesimmutrin.com--
21.04.2026Companiestrent.ai$13MUnited Kin...
25.02.2026BeyondMathbeyondmath.com$27MUnited Kin...
30.05.2025Trimtech T...trimtechtherapeutics.com$78M-
30.05.2025Companiessortera.bio--
26.12.2024Nucleranuclera.com$262.04MUnited Kin...
26.12.2024Forefront ...forefrontrf.com$31.24M-
18.05.2023Secondmindsecondmind.ai$16MUnited Kin...
18.05.2023AudioTelli...audiotelligence.com$12.54MUnited Kin...
18.05.2023Audio Anal...audioanalytic.com$17.5MUnited Kin...
Show more

News 678

DateTitleDescription
27.04.2023Complement Therapeutics appoints Dominic Moreland as Chief Financial OfficerComplement Therapeutics appoints Dominic Moreland as Chief Financial Officer Complement Therapeutics GmbH, a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appoint...
24.04.2023Riverlane raises £15m Series B to advance useful quantum computingRiverlane raises £15m Series B to advance useful quantum computing Quantum engineering company Riverlane today announced it has raised £15 million in a Series B funding. The round was led by Molten Ventures and included participation from s...
17.04.2023Cambridge Innovation Capital invests in Complement Therapeutics’ €72 Million Series A FundingCambridge Innovation Capital invests in Complement Therapeutics’ €72 Million Series A Funding Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life sciences businesses in the Cambridge ecosystem, has ...
17.04.2023VCs 'Complement' European biotech with $79M for retinal AAV gene therapy trial next yearVCs 'Complement' European biotech with $79M for retinal AAV gene therapy trial next year Endpoints News | By Kyle LaHucik, Associate Editor Complement Therapeutics raised a €72 million ($79.6 million) Series A to bankroll a Phase Ib of its ...
17.04.2023Complement Therapeutics closes $79M A round for gene therapy in geographic atrophyComplement Therapeutics closes $79M A round for gene therapy in geographic atrophy BioWorld | By Cormac Sheridan Complement Therapeutics GmbH raised €72 million (US$79.4 million) in a series A round to move into the clinic a novel gene ther...
12.04.2023Microbiotica announces collaboration with MSD in a Phase 1b Clinical Trial in melanomaMicrobiotica announces clinical trial collaboration with MSD to evaluate MB097 in combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in melanoma Microbiotica, a leader in discovering and developing microbiome-based ther...
12.04.2023Pragmatic Semiconductor announces appointment of semiconductor industry veteran, David Moore, as CEOPragmatic Semiconductor announced today that its Board of Directors has appointed semiconductor industry veteran, David Moore, as Chief Executive Officer Moore will join Pragmatic with immediate effect and takes over from Pragmatic’s co-Fou...
07.04.2023UK’s Cambridge tries to catch up with younger, innovative peerUK’s Cambridge tries to catch up with younger, innovative peer New initiative aims to promote UK city on the world stage Kendall Square in Massachusetts is seen as a model for the UK Bloomberg UK | By Lisa Pham Home to one of the world’s ol...
05.04.2023We celebrate 10 years of ‘Science WOW’We celebrate 10 years of ‘Science WOW’ For the past ten years, Cambridge Science Centre has inspired over 500,000 children and young people with immersive STEM experiences and mind-blowing events. To kick off the festivities, Cambridge Scie...
04.04.2023Cambridge Innovation Capital invests in Mosaic Therapeutics $28m Series A FundingCambridge Innovation Capital invests in Mosaic Therapeutics $28m Series A Funding Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life sciences businesses in the Cambridge ecosystem, has invested in ...
Show more

Mentions in press and media 86

DateTitleDescription
24.06.2026TRIMTECH Therapeutics Raises $47 Million Seed Funding To Advance Targeted Protein Degradation PortfolioTRIMTECH Therapeutics announced that it has raised an additional $14 million in seed funding, bringing the total round to $47 million. The additional financing was led by Johnson & Johnson’s corporate venture capital organization, Johns...
23.06.2026Trimtech Therapeutics Raises Additional $14M in Seed FundingTrimtech Therapeutics, a Cambridge, UK-based biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, raised additional $14M in Seed funding. Back...
22.05.2026Cambridge Wide Open Week 2026 announces top-tier keynotes & participating ventures for new expanded formatCambridge Wide Open Week 2026 has unveiled further details of its highly anticipated June 11–19 event as the life sciences festival expands across the UK’s innovation “Golden Triangle” for the very first time. Keynote speakers for the event...
19.05.2026Lansdowne Partners Ignites UK Innovation with New $150M VC FundLansdowne Partners launched a pivotal new venture capital fund. It targets high-potential UK innovation. The fund secured $150 million in its initial close. It aims to bridge critical funding gaps. UK companies emerging from university rese...
14.05.2026Lansdowne Partners: $150 Million First Close Announced For UK Innovation-Focused VC FundLansdowne Partners has launched a venture capital fund focused on supporting high-potential UK companies emerging from the country’s university research base and startup ecosystem. The fund announced a first close of $150 million and is tar...
14.05.2026Lansdowne Partners launches VC fund to scale UK innovation to global commercial successLansdowne Partners has launched a venture capital fund focused on backing high potential UK companies emerging from the country’s world class university research base and start up ecosystem. The fund announces a first close of $150 million ...
26.02.2026BeyondMath Secures $18.5M for Generative Physics AI ExpansionBeyondMath, a DeepTech leader, secured $18.5M in seed funding. This includes a $10M extension round. The company pioneers generative physics AI. It delivers engineering simulations 1000 times faster. This redefines design across aerospace, ...
25.02.2026BeyondMath secures $18.5M to expand its foundational physics AI modelLondon-based BeyondMath, a deeptech company that has developed a novel generative physics model, has raised a $10 million seed extension led by Cambridge Innovation Capital, with participation from existing investors including UP.Partners, ...
02.12.2025TRIMTECH Therapeutics appoints Alison Lawton as Chair of the BoardCambridge, UK, 2 December 2025: TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced the appointment ...
18.11.2025T-Therapeutics Secures $91 Million to Advance Bispecific TherapiesT-Therapeutics boosts Series A to $91M. New funds will push cancer, autoimmune bispecifics to trials. OpTiMus platform aims to unlock undruggable targets. Investors show strong confidence. **T-Therapeutics Secures $91 Million to Advance Bis...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In